Abstract
Rocuronium, a non-depolarizing neuromuscular blocking drug has a rapid onset of action, a comparatively low potency and, with a more favourable side effects profile than succinylcholine, it has become a popular alternative to that drug for rapid sequence inductions in anaesthesia. The rocuronium-binding cyclodextrin derivative sugammadex, prepared by per-6 substitution of the primary hydroxyls of γ-cyclodextrin with thiol ether-linked propionic acid side chains to extend the hydrophobic cavity to accommodate rocuronium, is used to reverse neuromuscular blockade by encapsulating the drug as an inclusion complex and removing it from the neuromuscular junction to the plasma. It has recently been suggested that sugammadex might also be of value in the management of rocuronium-induced anaphylaxis and this has been potentially supported by recent case reports. However, before sugammadex can be recommended for this purpose, it is important to establish whether or not the allergenic substituted ammonium groups at each end of the rocuronium molecule in the inclusion complex are masked within the cavity or left exposed for interaction with rocuronium-reactive IgE antibodies in the sera of rocuronium-allergic patients. Detailed experimental strategies and experimental protocols to investigate the allergenic potential of the sugammadex-rocuronium inclusion complex are presented and a possible explanation of the apparently rapid and successful reversal of anaphylaxis by administration of sugammadex is advanced and discussed.
Keywords: Sugammadex, perioperative anaphylaxis, cyclodextrins, drug allergy, rocuronium, drug-specific IgE.
Mini-Reviews in Medicinal Chemistry
Title:The Cyclodextrin Sugammadex and Anaphylaxis to Rocuronium: Is Rocuronium Still Potentially Allergenic in the Inclusion Complex Form?
Volume: 12 Issue: 8
Author(s): B. A. Baldo, N. J. McDonnell and N. H. Pham
Affiliation:
Keywords: Sugammadex, perioperative anaphylaxis, cyclodextrins, drug allergy, rocuronium, drug-specific IgE.
Abstract: Rocuronium, a non-depolarizing neuromuscular blocking drug has a rapid onset of action, a comparatively low potency and, with a more favourable side effects profile than succinylcholine, it has become a popular alternative to that drug for rapid sequence inductions in anaesthesia. The rocuronium-binding cyclodextrin derivative sugammadex, prepared by per-6 substitution of the primary hydroxyls of γ-cyclodextrin with thiol ether-linked propionic acid side chains to extend the hydrophobic cavity to accommodate rocuronium, is used to reverse neuromuscular blockade by encapsulating the drug as an inclusion complex and removing it from the neuromuscular junction to the plasma. It has recently been suggested that sugammadex might also be of value in the management of rocuronium-induced anaphylaxis and this has been potentially supported by recent case reports. However, before sugammadex can be recommended for this purpose, it is important to establish whether or not the allergenic substituted ammonium groups at each end of the rocuronium molecule in the inclusion complex are masked within the cavity or left exposed for interaction with rocuronium-reactive IgE antibodies in the sera of rocuronium-allergic patients. Detailed experimental strategies and experimental protocols to investigate the allergenic potential of the sugammadex-rocuronium inclusion complex are presented and a possible explanation of the apparently rapid and successful reversal of anaphylaxis by administration of sugammadex is advanced and discussed.
Export Options
About this article
Cite this article as:
A. Baldo B., J. McDonnell N. and H. Pham N., The Cyclodextrin Sugammadex and Anaphylaxis to Rocuronium: Is Rocuronium Still Potentially Allergenic in the Inclusion Complex Form?, Mini-Reviews in Medicinal Chemistry 2012; 12 (8) . https://dx.doi.org/10.2174/138955712801264828
DOI https://dx.doi.org/10.2174/138955712801264828 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Perspective on Quantum Mechanics Calculations in ADMET Predictions
Current Topics in Medicinal Chemistry microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews Respiratory Gas Exchange During Exercise in Children with Congenital Heart Disease: Methodology and Clinical Concepts
Current Respiratory Medicine Reviews Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Phospholipase A2 Inhibitors as Potential Anti-Inflammatory Agents
Current Pharmaceutical Design Invasive Aspergillosis: New Insights into Disease, Diagnostic and Treatment
Current Pharmaceutical Design New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology Functional Properties of Pentacyclic Triterpenes Contained in "Orujo" Olive Oil
Current Nutrition & Food Science Editorial [Hot Topic Intracellular Calcium Signaling: Holding the Balance between Health and Disease Guest Editor: Luca Munaron]
Current Medicinal Chemistry Neuroimmune Activation in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Current Vascular Pharmacology Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Biocatalysis in the Pharmaceutical Industry. A Greener Future
Current Green Chemistry Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews Staged Starnes Operation Preserving Patent Ductus Arteriosus for Neonates with Ebsteins Anomaly and Pulmonary Atresia
Current Cardiology Reviews Mechanosensitive Ion Channels as Drug Targets
Current Drug Targets - CNS & Neurological Disorders Tissue Engineering for Post-Myocardial Infarction Ventricular Remodeling
Mini-Reviews in Medicinal Chemistry